Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations

Targeted therapies have substantially changed the management of non-small cell lung cancer (NSCLC) patients with driver oncogenes. Given the high frequency, EGFR and ALK aberrations were the first to be detected and paved the way for tyrosine kinase inhibitor (TKI) treatments. Other kinases such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Dugay, Frédéric, Llamas-Gutierrez, Francisco, Gournay, Marjory, Medane, Sarah, Mazet, François, Chiforeanu, Dan Christian, Becker, Emmanuelle, Lamy, Régine, Léna, Hervé, Rioux-Leclercq, Nathalie, Belaud-Rotureau, Marc-Antoine, Cabillic, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581114/
https://www.ncbi.nlm.nih.gov/pubmed/28881815
http://dx.doi.org/10.18632/oncotarget.18408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581114/
https://www.ncbi.nlm.nih.gov/pubmed/28881815
http://dx.doi.org/10.18632/oncotarget.18408

Ejemplares similares